Navigation Links
Step forward in foot-and-mouth disease understanding
Date:12/9/2011

Researchers at the University of Leeds have been studying an enzyme called 3D which plays a vital role in the replication of the virus behind the disease. They have found that this enzyme forms fibrous structures (or fibrils) during the replication process. What's more, they have found a molecule which can prevent these fibrils forming.

The project was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and its findings have been published by the Journal of Virology.

"It's too much of a jump to say that we've found a potential drug target for treatment of foot-and-mouth disease because there's still such a lot we don't know," says Dr Nicola Stonehouse of the University of Leeds' Faculty of Biological Sciences. "However, we do think these findings are significant and provide us with a new avenue for exploration."

Foot-and-mouth is a one of the most readily transmissible diseases known to man, but the mechanisms by which it infects animals are not well understood. The virus responsible for the disease is able to reproduce very quickly, enabling it to cause widespread devastation in a short space of time. The 2001 outbreak in the UK resulted in the deaths of around seven million sheep and cattle at an extremely high cost to the British agricultural sector. Another, more contained outbreak, occurred in 2007.

In laboratory experiments, the research team were able to see that the 3D enzyme forms fibrils when it is copying genetic information it requires to replicate. The implications of these fibrils are not yet fully understood, but it is thought they may play an important role in the reproduction process. If this is the case, having already found a molecule to block the fibril formation could be significant.

"The next stage of our research will be to investigate these fibrils further, to look at their structure and purpose," says PhD student Kris Holmes, who has been working on the project.

Because FMD is classed as a dangerous pathogen, only one laboratory in the UK the Institute for Animal Health at Pirbright, in Surrey is licensed to work with the actual virus. In this research, the Leeds team used a simple, non-harmful model of the virus.


'/>"/>
Contact: Dr Nicola Stonehouse
n.j.stonehouse@leeds.ac.uk
44-113-343-3102
University of Leeds
Source:Eurekalert

Related biology news :

1. Stampede charges computational science forward in tackling complex societal challenges
2. Big steps forward in human functional brain imaging, but collaborations key to patient benefit
3. Hips take walking in stride; ankles put best foot forward in run
4. ONR, Marine Corps show alternative energy use at forward operating bases can save dollars, lives
5. Stroke research takes 2 steps forward
6. $1.6 million to take forward breakthrough research in heart disease
7. Growing drought-tolerant crops inching forward
8. CAKE offers way forward for climate change adaptation
9. A fat forward research tool
10. Meteosat Third Generation takes a step forward
11. First adhere, then detach and glide forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology: